Bcl-x(L) and Bcl-2 expression in squamous cell carcinoma of the head and neck

Cancer

Volumn 85, Issue 1, 1999, Pages 164-170

  Pena, John C ^a,b   Thompson, Craig B ^a,b   Recant, Wendy ^b   Vokes, Everett E ^b   Rudin, Charles M ^a,b,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Bcl x(L); Bcl 2; Head and neck cancer; p53; Squamous cell carcinoma

Indexed keywords

ANTIBODY; CISPLATIN; FLUOROURACIL; FOLINIC ACID; HYDROXYUREA; METHOTREXATE; PIRITREXIM; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P53; BCL2L1 PROTEIN, HUMAN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTO ONCOGENE; SQUAMOUS CELL CARCINOMA; GENETICS; HEAD AND NECK TUMOR; MIDDLE AGED; MORTALITY; SURVIVAL RATE;

BCL-X PROTEIN; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032589824     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990101)85:1<164::AID-CNCR23>3.0.CO;2-Q     Document Type: Article

References (59)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;65:5-27.
2. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993;54:594-606.
3. Vokes EE, Weichselbaum RR, Lippman S, Hong WK. Head and neck cancer. New Engl J Med 1993;328:184-94.
4. Vokes EE. Combined-modality therapy of head and neck cancer. Oncology 1997;11(9):27-30.
5. Vokes EE, Athanasiadis I. Chemotherapy for squamous cell carcinoma head and neck: the future is now. Ann Oncol 1996;7:15-29.
6. Dimery IW, Hong WK. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 1993;85: 95-111.
7. Field JK, Spandidos DA, Stell PM, Vaughn ED, Evan GI, Moore JP. Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. Oncogene 1989;4:1463-8.
8. Schantz SP, Spitz MR, Hsu TC. Mutagen sensitivity in patients with head and neck cancers: a biologic marker for risk of multiple primary malignancies. J Natl Cancer Inst 1990; 82:1773-5.
9. Schipper JH, Frixen UH, Behrens J, Unger A, Jahnke K, Birchmeier W. E-cadherin expression insquamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Res 1991;51:6328-37.
10. Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993;11:1873-8.
11. Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E, Balm A. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 1995;55: 975-8.
12. Koch WM, Brennan JA, Zahurak M, Goodman SN, Westra WH, Schwab D, et al. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:1580-6.
13. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.
14. Rudin CM, Thompson CB. Apoptosis and cancer. In: Vogelstein B, Kinzler KW, editors. The Genetic Basis by Human Cancer. New York: McGraw Hill, 1997; 193-204.
15. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992;69:119-28.
16. White E. Life, death, and the pursuit of apoptosis. Genes Dev 1996;10:1-15.
17. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 1996;88:386-401.
18. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med 1997;3:614-20.
19. Campos L, Rouault J-P, Sabido O, Oriol P, Roubi N, Vasselon C, et al. High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993;81:3091-6.
20. Hague A, Moorghen M, Hicks D, Chapman M, Paraskeva C. BCL-2 expression in human colorectal adenomas and carcinomas. Oncogene 1994;9:3367-70.
21. L is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res 1995;55: 2576-82.
22. L transgene promotes malignant conversion of chemically initiaited skin papillomas. Cancer Res 1998;58:2111-6.
23. Miyashita T, Reed JC. Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 1992;52:5407-11.
24. Ohmori T, Podack ER, Nishio K, Takahashi M, Miyahara Y, Taked Y, et al. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by Bcl-2. Biochem Biophys Res Comm 1993;192(1):30-6.
25. Walton MI, Whysong D, O'Connor PM, Hockenbery D, Korsmeyer SJ, Kohn KW. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res 1993;55:1853-61.
26. Dole M, Nuñez G, Merchant AK, Maybaum J, Rode CK, Bloch CA, et al. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 1994;54:3253-59.
27. L can confer a multidrug resistance phenotype. Blood 1995;86:1903-10.
28. L by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Dif 1995;6:363-70.
29. Vokes EE, Schilsky RL, Weichselbaum RR, Kozlaff MF, Panje WR. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol 1990;8:241-7.
30. Vokes EE, Haraf DJ, McEvilly J-M, Mick R, Kozloff MF, Goldman MD, et al. Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach. Ann Oncol 1992;3:79-81.
31. Vokes EE, Ratain MJ, Mick R, McEvilly JM, Haraf D, Kozloff M, et al. Cisplatin, fluorouracil, and leukovorin augmented by interferon alpha-2b in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol 1993;11:360-8.
32. Vokes EE, Kies M, Haraf DJ, Mick R, Moran WJ, Kozloff M, et al. Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease. J Clin Oncol 1995;13: 876-83.
33. Vokes EE, Mick R, Kies MS, Dolan ME, Malone D, Athanasiadis I, et al. Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol 1996;14:1663-71.
34. Pena JC, Fuchs E, Thompson CB. Bcl-x expression influences keratinocyte cell survival but not terminal differentiation. Cell Growth Dif 1997;8:619-29.
35. L and Bcl-2 to prevent apoptosis can be differentially regulated. Cell Death Dif 1996;3:113-8.
36. Jacks T, Weinberg RA. Cell-cycle control and its watchman. Nature 1996;381:643-4.
37. Lane DP. p53, Guardian of the genome. Nature 1992;358: 15-6.
38. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
39. Gallo O, Bianchi S, Porfirio B. Bcl-2 overexpression and smoking history in head and neck cancer. J Natl Cancer Inst 1995;87:1024-5.
40. Wilson GD, Grover R, Richman PI, Daley FM, Saunders MI, Dische S. BCL-2 expression correlates with favorable outcome in head and neck cancer treated by accelerated radiotherapy. Anticancer Res 1996;16:2403-8.
41. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
42. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
43. Simonian PL, Grillot D-AM, Nuñez G. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood 1997;90:1208-16.
44. L and Bcl-2, displaces Bax and promotes cell death. Cell 1995;80:285-91.
45. Vairo G, Innes KM, Adams JM. Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene 1996;13:1511-9.
46. O'Reilly LA, Huang DCS, Strasser A. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J 1996;15:6979-90.
47. Huang DCS, O'Reilly LA, Strasser A, Cory S. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J 1997;16:4628-38.
48. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, et al. Bcl-2 protein in non-small-cell lung carcinoma. New Engl J Med 1993;329:690-4.
49. Higashiyama M, Doi O, Kodama K, Yokouchi H, Nakamori S, Tateishi R. Bcl-2 oncoprotein in surgically resected non-small cell lung cancer: possibly favorable prognostic factor in association with low incidence of distant metastasis. J Surg Oncol 1997;64:48-54.
50. Apolinario RM, van der Valk P, de Jong JS, Deville W, van Ark-Otte J, Dingemans A-MC, et al. Prognostic value of the expression of p53, Bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol 1997;15:2456-66.
51. Baretton GB, Diebold J, Christoforis G, Vogt M, Müller C, Dopfer K, et al. apoptosis and immunohistochemical Bcl-2 expression in colorectal adenomas and carcinomas: aspects of carcinogenesis and prognostic significance. Cancer 1996; 77:255-64.
52. Diebold J, Baretton G, Felchner M, Meier W, Dopfer K, Schmidt M, et al. Bcl-2 Expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol 1996;105: 341-9.
53. Lipponen P, Eskelinen M, Syrjänen. Expression of tumour-suppressor gene Rb, apoptosis-suppressing protein Bcl-2 and c-Myc have no independent prognostic value in renal adenocarcinoma. Br J Cancer 1995;71:863-7.
54. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL. Bcl-2 In normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1994;69:135-9.
55. Joensuu H, Pylkkänen, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 1994;145:1191-8.
56. Silvestrini R, Veneroni S, Daidone MG, Renini E, Boracchi P, Mezzetti M, et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994;86:499-504.
57. Hellemans P, van Dam PA, Weyler J, van Oosterom AT, Buytaert P, Van Marck E. Prognostic value of Bcl-2 expression in invasive breast cancer. Br J Cancer 1995;72:354-60.
58. Lipponen P, Pietiläinen T, Kosma V-M, Aaltomaa S, Eskelinen M, Syrjänen K. Apoptosis suppressing protein Bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol 1995;177:49-55.
59. Olopade OI, Adeyanju MO, Safa AR, Hagos F, Mick R, Thompson CB, et al. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J Sci AM 1997;3:230-7.